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Abstract In past decades, studies focusing on new chemotherapeutic agents for
patients with inoperable non-small-cell lung cancer have reported only
modest gains in survival. These health gains are achieved at considerable cost,
but economic evidence is lacking on superiority of one agent in terms of cost
effectiveness. The objective of this systematic review was to assess fully
published cost-effectiveness studies comparing the new agents docetaxel,
paclitaxel, vinorelbine, gemcitabine and pemetrexed, and the targeted thera-
pies erlotinib and gefitinib with one another.
We performed systematic searches in the bibliographic databases PubMed,
EMBASE and Health Economic Evaluations (HEED) [via the Cochrane
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Library] for fully published studies from the past 10 years. Studies were
screened by two independent reviewers according to a priori inclusion criteria.
The methodological quality of the included studies was evaluated by two
independent reviewers using standardized assessment tools.
A total of 222 potential studies were identified; 11 studies and six reviews
were included. The methodological quality of the full economic evaluations
was fairly good. Transparency in costs and resource use, details on statistical
tests and sensitivity analysis were points for improvement. In first-line treatment,
gemcitabine+cisplatin was cost effective compared with other platinum-based
regimens (paclitaxel, docetaxel and vinorelbine). In one study, pemetrexed+
cisplatin was cost effective compared with gemcitabine+cisplatin in patients
with non-squamous-cell carcinoma. In second-line treatment, docetaxel was
cost effective compared with best supportive care; erlotinib was cost effective
compared with placebo; and docetaxel and pemetrexed were dominated by
erlotinib.
We found indications of superiority in terms of cost effectiveness for gemci-
tabine+cisplatin in a first-line setting, and for erlotinib in a second-line setting.
Key points for decision makers
 Due to the small number of studies, heterogeneity between studies and lack of a clear and
consistent definition of best supportive care (BSC) in each study, strong conclusions cannot
be drawn
 The estimates of key parameters, model assumptions and calculations in modelling studies
were often poorly reported
 However, there was reasonable consensus between studies that gemcitabine+cisplatin is a
cost-effective option for first-line treatment of non-small-cell lung cancer, although peme-
trexed+cisplatin appears more cost effective for non-squamous-cell carcinoma
 In second-line treatment, docetaxel appears to be cost effective compared with BSC, while
erlotinib may be a cost-effective alternative compared with docetaxel
Lung cancer is the most common cause of
cancer-related death in the Western world.[1]
Approximately 85% of all lung cancer cases
are of the subtype non-small-cell lung cancer
(NSCLC).[2] Many patients with NSCLC are di-
agnosed in an advanced stage (IIIB or IV), for
which surgical resection is not recommended.
These patients are treated with radiotherapy and/
or (combinations of) chemotherapeutic agents.[2,3]
In past decades, research into chemother-
apeutic treatments for patients with inoperable
NSCLC has led to only modest gains in survival.
Nevertheless, trials have generally supported the
use of two chemotherapeutic drugs rather than
one in terms of response rates, survival and quality
of life (QOL). A recent systematic review[4] of the
literature concerning the effectiveness in terms of
response rates, survival, progression-free survival
(PFS) and QOL of new drugs such as docetaxel,
gemcitabine, paclitaxel, pemetrexed and vinor-
elbine, also known as third-generation agents,
concluded that no single one among these new
drugs was clearly superior over the others when
used in combination with a platinum agent.
The modest improvements in the care of ad-
vanced NSCLC patients are achieved at con-
siderable cost.[5] Therefore, the economic evaluation
of new chemotherapeutic drugs has become
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important for health policy makers who are
charged with allocating limited funds to various
healthcare programmes. The evidence with re-
spect to cost effectiveness requires updating,
especially because of the intensive research efforts
in the last decade to improve treatment outcomes
for NSCLC patients. Reviews available in the
literature up until now mainly focused on third-
generation agents compared with best supportive
care (BSC) or with second-generation agents,
which are older agents such as vindesine and mito-
mysin. Because second-generation drugs are no
longer recommended, we chose to include in this
review only studies comparing the third-generation
agents docetaxel, gemcitabine, paclitaxel, peme-
trexed and vinorelbine with each other or with
BSC. Moreover, we included cost-effectiveness an-
alyses (CEAs) focusing on the new targeted thera-
pies erlotinib and gefitinib, as recently these drugs
have shown positive results in phase III trials and are
approved as second-line therapy and maintenance
therapy (erlotinib) and as all-line therapy (gefitinib).
1. Literature Review
1.1 Search Strategy
We performed systematic searches in the bib-
liographic databases PubMed, EMBASE and
Health Economic Evaluations (HEED) [via the
Cochrane Library] for papers published between
January 2001 and October 2010. Search terms
included controlledmedical subject heading (MeSH)
terms in PubMed and Emtree in EMBASE, as
well as free-text terms. We used free-text terms
only in the HEED database. Search terms ex-
pressing non-small-cell lung carcinoma were used
in combination with search terms representing
expensive chemotherapies and terms for cost ef-
fectiveness. The search strategy is presented in
table S1 in the Supplemental Digital Content (SDC),
http://links.adisonline.com/PCZ/A132.
1.2 Selection Phase
To identify relevant studies, two independent
reviewers (MLB and EPJ) screened the studies
resulting from the search strategy, based on title
and abstract. Studies were considered eligible if
they met the following inclusion criteria:
 evaluated the agents of interest as one of the
main topics in a full economic evaluation,
more specifically in aCEAor cost-utility analysis
(CUA);
 reported on at least one of the following out-
comes: costs and QOL, or costs and survival;
 were full-text articles written in either Dutch
or English.
Studies were excluded for the following reasons:
 included new agents, but the primary objective
of the study was to evaluate a non-eligible
agent or therapy (except for BSC or placebo);
 included a new agent but the only other com-
parator arm was a non-eligible agent;
 solely focused on the cost effectiveness of the
treatment of metastases instead of primary
tumours.
The results of the screenings by both reviewers
were compared, and any disagreements were
discussed. If disagreement remained, a third re-
viewer (VMHC) was consulted in order to reach a
consensus. The references of the selected articles
were searched for relevant publications.
1.3 Data Assessment
The full text of each of the selected studies was
obtained for further review. Two reviewers (MLB
and VMHC) independently evaluated the meth-
odological quality of the full economic evaluations
using the British Medical Journal (BMJ) 35-item
checklist for authors and peer reviewers of eco-
nomic submissions.[6] Again, the results were com-
pared and disagreements were discussed in order
to reach consensus. The objective of a critical ap-
praisal is to assess whether the included studies
describe methods, assumptions, models and po-
tential biases in a way that is transparent and
supported by the evidence, in order to enable ap-
praisal by any critical reader. Although no check-
list has been formally validated, the BMJ checklist
byDrummond and Jefferson[6] is recommended for
Cochrane reviews.[7]
As the BMJ checklist by Drummond and
Jefferson[6] does not provide for the assessment of
modelling studies, we supplemented the evaluation
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of methodological quality with a framework
proposed by Philips et al.[8] This framework con-
sists of three dimensions of quality: structure, data
and consistency, which are each subdivided into
several questions for critical appraisal, such as the
rationale for model structure, justification of iden-
tification of data and the extent to which consis-
tency of the results with other models is discussed.
1.4 Search Results
The literature search generated a total of
368 references: 113 in PubMed, 188 in EMBASE
and 67 in HEED from the Cochrane Library.
After removing 146 duplicates that were included
in more than one database, 222 papers remained.
Of these 222 papers, 30 met the inclusion criteria,
of which seven were conference abstracts only,
two were not available in full text in time after two
requests, one was only available in Portuguese, two
were reports describing a manufacturer’s economic
evaluation, and one was a comment on another
included study. The flow chart of the search and
selection process is presented in figure 1.
Among the 17 remaining studies, six were re-
views, six were CEAs and five were CUAs. We
present an overview of the reviews, followed by a
summary of the CEAs and CUAs by type of treat-
ment: first-line treatment (four studies), mainten-
ance therapy (one study) and second-line treatment
(six studies).
2. Quality of the Evidence
The results of the assessment of the methodo-
logical quality for first- and second-line treat-
Records screened (n = 222) Records excluded (n = 192)
Full-text articles excluded:
• conference abstracts (n = 7)
• no full text available in time (n = 2)
• article in Portuguese (n = 1)
• publication type was a comment
(n = 1)
• ERG report assessing
manufacturer's economic evaluation
[no reference] (n = 2)Studies included in qualitative
synthesis (n = 17)
Records identified through database
search (n = 368)
Records after duplicates removed
(n = 222)
Full-text articles assessed for
eligibility (n = 30)
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Fig. 1. Flowchart of the search and selection procedure for cost-effectiveness analyses. ERG =Evidence Review Group.
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ment and maintenance therapy, as well as the
assessment of the modelling studies, are present-
ed in tables S2, S3 and S4 in the SDC. A few items
were consistently under-reported, such as ‘are the
ranges over which the variables were varied for
sensitivity analysis justified?’,[9-16] ‘were details of
statistical tests and confidence intervals of sto-
chastic data reported?’[10-16] and ‘were quantities
of resource use reported separately from their
unit costs?’.[12,13,16-18]
3. Summary of the Evidence from
Reviews Published between 2001
and 2010
The six reviews identified by our search strategy
are summarized in table I and discussed below.
Three reviews[20-22] assessed the literature with re-
spect to any treatment for NSCLC. As these re-
views were quite broad in the range of included
treatments, no strong conclusions regarding spe-
cific chemotherapeutic agents were drawn. In gen-
eral, it was suggested that therapies for NSCLC
were cost effective or even cost saving compared
with BSC, but that additional (cost-utility) studies
were warranted. The review conducted by Clegg
et al.[19] in 2001 evaluated the cost effectiveness
of third-generation agents docetaxel, gemcitabine,
paclitaxel and vinorelbine compared with BSC,
and found all of these agents to extend life at rea-
sonable cost (d6249–15 283 per life-year gained
[LYG]).
The two remaining reviews[23,24] recently eval-
uated the cost effectiveness of erlotinib.
Lyseng-Williamson[24] included ten CEAs eval-
uating erlotinib after the failure of at least one
chemotherapy regimen; three of these were fully
published studies. Overall, in eight studies, erlo-
tinib dominated docetaxel (erlotinib was cheaper
and more effective). Of five studies comparing
erlotinib with pemetrexed, three concluded that
erlotinib dominated pemetrexed, and the two re-
maining studies reported erlotinib to be cost
saving compared with pemetrexed (erlotinib was
cheaper and equally effective). The author con-
cluded that, in patients with advanced NSCLC,
second- or third-line therapy with erlotinib was
clinically effective in improving survival, and the
available pharmacoeconomic data supported the
use of erlotinib as a cost-saving treatment com-
pared with docetaxel and pemetrexed.
In 2009, Carlson[23] reviewed eight CEAs
of erlotinib, five of which were also included
by Lyseng-Williamson.[24] Similarly to Lyseng-
Williamson, the author concluded that erlotinib
provided equivalent or additional effectiveness
compared with BSC and pemetrexed. The main
difference between erlotinib and the alternative
treatments docetaxel and pemetrexed appeared
to be the convenience and cost savings associated
with oral versus intravenous administration, as
well as the favourable toxicity profile of erlotinib.
Both reviews included (conference) abstracts as
well as peer-reviewed full publications.
4. First-Line Treatment
All of the studies focusing on first-line treat-
ment included gemcitabine in one of the treatment
arms, either in combination with cisplatin (three
studies[12,14,18]) or in combination with docetaxel
(one study[25]). Table II provides an overview of
all studies for first-line treatment. In table III, the
reported costs and benefits in the three studies
with a gemcitabine+cisplatin arm[12,14,18] are pre-
sented in detail. Table S5 in the SDC presents the
included clinical and cost inputs for all first-line
treatment studies.
Neymark et al.[18] conducted a study in the
Netherlands, comparing paclitaxel+cisplatin with
gemcitabine+cisplatin and with gemcitabine+
paclitaxel. For both comparisons, the results were
presented on a cost-effectiveness plane, showing
the joint distribution of 5000 bootstrap replicates
of differences in costs and survival time in years.
The authors found a 72% probability that gem-
citabine+cisplatin improves survival and reduces
costs compared with paclitaxel+cisplatin. The dif-
ference in costs was explained by the chemotherapy
costs, paclitaxel being a more expensive drug than
gemcitabine (h8654 vs h5234 per patient [year 2002
values]). Comparing paclitaxel+cisplatin with gem-
citabine+paclitaxel resulted in a probability of 82%
that gemcitabine+paclitaxel would reduce mean sur-
vival while increasing costs. The authors concluded
that gemcitabine+paclitaxel is clearly dominated by
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paclitaxel+cisplatin, which in turn is dominated
by gemcitabine+cisplatin.
The second study considering the gemcitabine+
cisplatin regimen was the UK cost-effectiveness
study by Lees et al.[14] The authors compared
gemcitabine+cisplatin with paclitaxel+cisplatin,
paclitaxel+carboplatin, docetaxel+cisplatin and
vinorelbine+cisplatin. Overall survival was similar
for the treatment arms containing either doc-
etaxel or paclitaxel, but median survival time was
increased for gemcitabine+cisplatin compared
with vinorelbine+cisplatin (42 weeks vs 35 weeks;
survival times of other arms were not reported).
PFS was reported for all regimens. Compared with
all other regimens, gemcitabine+cisplatin resulted
in incremental progression-free life-years ranging
from 0.083 to 0.135 (see table III). Main cost
drivers in this study were the costs of chemothe-
rapy and its administration. The authors con-
cluded that the gemcitabine+cisplatin regimen
provided value for money relative to other novel
regimens. The authors did not report any incre-
mental cost-effectiveness ratios (ICERs), nor any
incremental analysis of the treatment regimens.
Klein et al.[12] assessed the cost effectiveness of
pemetrexed+cisplatin compared with gemcitabi-
ne+cisplatin in a general stage IIIB/IV population
in the US, as well as in patients with non-squamous
cell carcinoma. In this latter subgroup, they found
an ICER of $US83537 per LYG for pemetrexed+
cisplatin compared with gemcitabine+cisplatin
(year 2002 values), based on incremental costs of
$US4509 and incremental life-years of 0.054. The
CUA resulted in an ICER of $US132 829 per
QALY gained, based on $US4509 incremental
costs and 0.0339 incremental QALYs. In the total
group (non-squamous- and squamous-cell carci-
noma), the incremental costs for pemetrexed were
higher than in the non-squamous group, and
LYG and QALYs were lower, resulting in higher
ICERs ($US104 577 per LYG; $US179 597 per
QALY). In the US, the value of $US50 000 per
QALY gained is frequently quoted as being the
threshold for cost effectiveness, but a range of
$US109 000–297 000 is more likely to be con-
sistent with societal preferences.[30] In this regard,
Klein et al.[12] considered pemetrexed+cisplatin
to be cost effective compared with gemcitabine+Ta
b
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cisplatin, regardless of histological subtype. Al-
though the authors included all relevant costs
from a healthcare payer perspective, the costs for
adverse events within both treatment arms were
considered equal. This assumption may have
biased the ICERs against pemetrexed+cisplatin,
as the original trial[31] reported a higher incidence
of serious adverse events in the gemcitabine
arm. A sensitivity analysis was conducted to ad-
dress this assumption, resulting in an ICER of
$US39000–44000 per LYG, corresponding with a
45–55% decrease in adverse events for pemetrexed.
Maniadakis et al.[25] compared gemcitabine+
docetaxel with docetaxel alone in Greece and re-
ported an ICER of h9538 per LYG (year 2005
values), which is far below international thresh-
olds used to accept implementation and reim-
bursement of new treatments. They concluded
that gemcitabine+docetaxel is a cost-effective treat-
ment option in the Greek healthcare setting,
compared with docetaxel monotherapy.
To summarize, in two studies,[14,18] gemcitabine+
cisplatin was a cost-effective treatment option
compared with paclitaxel+cisplatin and, in one
study,[14] compared with paclitaxel+carboplatin,
docetaxel+cisplatin and vinorelbine+cisplatin.
However, pemetrexed+cisplatin was cost effective
compared with gemcitabine+cisplatin, especially
in the subgroup of patients with non-squamous-
cell carcinoma.[12]
5. Maintenance Therapy
One US study[13] was available for maintenance
therapy. The primary objective was to estimate the
cost effectiveness of maintenance therapy with pe-
metrexed compared with observation, each in ad-
dition to BSC, in patients with advanced NSCLC
who have completed, without progression, at
least four cycles of first-line platinum chemothe-
rapy. The median overall survival for patients
treated with pemetrexed compared with observation
was 15.5 months versus 10.3 months, respective-
ly, in patients with non-squamous-cell histology,
and 13.4 months versus 10.6 months, respec-
tively, in the total study population. Additionally,
patients treated with pemetrexed had a longer
PFS compared with observation (non-squamous:Ta
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2.6 months; total: 1.7 months). Major drivers of
cost differences were drug costs, as well as costs
for serious adverse events. The incremental cost
per LYG was $US122 371 for pemetrexed com-
pared with observation in the non-squamous
population and $US205 597 in the total study
population (year 2009 values). The authors con-
cluded that histology is important in targeting the
appropriate patients for pemetrexed maintenance
therapy.
6. Second-Line Treatment
Five of six studies focusing on second-line
treatment included docetaxel in one of the treat-
ment arms, either as a comparator or as the re-
ference agent. Table IV presents an overview of
the studies. An overview of the included costs and
benefits for all treatment arms of the six studies is
presented in table S6 in the SDC. The total and
incremental costs, as well as survival estimates,
for the five studies with a docetaxel arm are pre-
sented in table V.
Holmes et al.[11] and Leighl et al.[15] compared
docetaxel 75mg with BSC. Both studies considered
survival and resource use based on the same trial,
TAX 317,[32] although they used different meth-
ods to estimate the key parameters in their anal-
yses. The cost effectiveness of docetaxel versus
BSC was found to be $Can31 776 per LYG in
Canada (year 1999 values)[15] and d13 863 per
LYG in the UK (year 2000/2001 values),[11] and
both studies concluded that docetaxel is cost ef-
fective from a healthcare system perspective. The
main cause of the difference in ICERs was related
to costs for hospitalization and for adverse events,
which were not included in Holmes et al.,[11] where-
as they were included by Leighl et al.[15]
Asukai et al.[17] performed a CUA comparing
pemetrexed with docetaxel. QOL estimates were
based on utility values, which were obtained from
a study of 100 participants. They found that,
compared with docetaxel, pemetrexed was asso-
ciated with higher chemotherapy costs and lower
costs for adverse events. Median survival and
PFS were both higher in the pemetrexed arm (9.3
vs 8.0 months and 3.1 vs 3.0 months, respective-
ly). Based on the mean values of survival and PFS
in both arms, this resulted in an ICER of h17 225
per LYG and h23 967 per QALY gained for pe-
metrexed compared with docetaxel (year 2007
values). The lower number of reported adverse
events in the pemetrexed arm contributed favou-
rably to the health-related QOL of patients treated
with pemetrexed. Given the Spanish threshold of
h30 000 per QALY gained, pemetrexed was con-
sidered cost effective in comparison with doc-
etaxel in Spain.
Table III. Detailed overview of results of the studies of first-line treatment that have gemcitabine+cisplatin (GEM+CIS) as one of the treatment
arms
Study, comparator Costs Survival (y)
GEM+CIS arm comparator arm incremental costs GEM+CIS arm comparator arm incremental survival
Klein et al.[12] Median survival
PEM+CIS $US61 008 $US65 517 -$US4509 0.87 0.98 -0.054a
Neymark et al.[18] Mean survival
PAC+CIS h13 944 h16 662 -h2718 0.98 0.94 0.04
PAC+GEM h13 944 h17 377 -h3433 0.98 0.80 0.18
Lees et al.[14] Progression-free survival
PAC+CIS £5537 £9043 -£3506 0.375 0.292 0.083
PAC+CAR £5537 £8444 -£2907 0.375 0.300 0.075
DOC+CIS £5537 £5779 -£242 0.375 0.275 0.100
VIN+CISb £4477 £5048 -£571 0.808 0.673 0.135
a Incremental survival resulting from running the model. Median survival of both arms presented here was directly taken from the trial and
cannot be subtracted to obtain incremental survival.
b The results for VIN+CIS vs GEM+CIS were obtained from another trial.
CAR = carboplatin; DOC =docetaxel; PAC =paclitaxel; PEM = pemetrexed; VIN = vinorelbine.
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Carlson et al.[10] evaluated costs and effec-
tiveness of docetaxel, pemetrexed and erlotinib
from a US payer perspective. Overall survival
was assumed to be equal in all treatment arms, as
was PFS. When QALYs were used as the health
outcome measure, erlotinib provided an incre-
mental QALY gain of 0.01 compared with doc-
etaxel and pemetrexed, due to less severe adverse
events and the oral administration of erlotinib
versus the intravenous administration of pemetrexed
and docetaxel. In the CUA, erlotinib dominated
both docetaxel and pemetrexed.
Lewis et al.[16] also compared erlotinib with
docetaxel in a CUA, but from a UKNHS perspec-
tive. The survival was derived from Kaplan-Meier
curves of the same trials as the studies by Carlson
et al.,[10] Holmes et al.[11] and Leighl et al.[15]
(BR.21 for erlotinib,[34] and TAX 317 for doc-
etaxel[32]). The BR.21 trial included more patients
with a poor performance status (WHO perfor-
mance status of 3) than the TAX 317 trial.Whereas
Carlson et al.[10] adjusted for this potential bias,
Lewis et al.[16] did not. In addition, Lewis et al.[16]
assumed PFS to be equal to the mean treatment
duration (3.33 months in docetaxel arm and 4.11
months in erlotinib arm), while Carlson et al.[10]
did not report how PFS was estimated (4 months
in both arms). With the exception of the costs
associated with disease progression, Lewis et al.[16]
reported similar cost estimates as Carlson et al.[10]
Lewis et al.[16] found erlotinib to dominate docetax-
el, although the incremental costs and incremental
effects were very small. The cost-effectiveness plane
showed an equal distribution of incremental costs
and effects among the four quadrants.
Bradbury et al.[9] evaluated the cost effective-
ness of erlotinib piggybacked alongside the actual
BR.21 trial, from a Canadian public healthcare
system perspective. As such, data on resource utili-
zation and costs were available and taken di-
rectly from the trial. The ICER of erlotinib was
$Can94 638 per LYG versus placebo (year 2007
values). In addition to their principal analyses,
Bradbury et al.[9] evaluated the cost effectiveness
of erlotinib for subgroups characterized by molec-
ular features that are expected to be related to
response to erlotinib. The greatest change in the
ICER compared with the total group was found
in the subgroup of patients with a high epidermal
growth factor receptor (EGFR)-gene copy num-
ber and in the subgroup of never-smokers (ICER
$Can33353 and $Can39487 per LYG, respectively).
To summarize, docetaxel seems a cost-effective
treatment option when compared with BSC. The
adverse events associated with docetaxel were
febrile neutropenia and neutropenia, which are
both related to hospitalization and, therefore, were
the main drivers of costs for docetaxel.[10,15,17]
One study[11] did not take adverse events into
account. Pemetrexed was a more expensive drug
Table V. Detailed overview of results of the studies of second-line treatment that have docetaxel (DOC) as one of the treatment arms
Study,
comparator
Costs Survival (y)
DOC arm comparator
arm
incremental
costs
DOC arm comparator
arm
incremental
survival
Leighl et al.[15] Mean survival
BSC $Can17 739 $Can6 935 $Can10 804 0.79 0.45 0.34
Holmes et al.[11] Incremental survival
BSC £4 432 £0 £4432 0.32 0.00 0.32
Asukai et al.[17] Mean survival
PEM h32 343 h34 677 -h2334 0.89 1.03 -0.14
Carlson et al.[10] Overall survival
PEM $US39 104 $US43 759 -$US4655 0.75 0.75 0.00
ERL $US39 104 $US36 977 $US2127 0.75 0.75 0.00
Lewis et al.[16] QALYs
ERL £13 956 £13 370 £226 0.206 0.238 0.032
BSC =best supportive care; ERL = erlotinib; PEM =pemetrexed.
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than docetaxel, with less adverse events, in two
independent studies,[10,17] although each was per-
formed in a different country. In one of these stud-
ies,[17] pemetrexed was cost effective compared
with docetaxel but was dominated by erlotinib.
Erlotinib was cost effective compared with doc-
etaxel in a UK study[16] and borderline cost effec-
tive compared with BSC in a Canadian study.[9]
The Canadian study found lower ICERs in never-
smokers and in a subgroup of patients with a high
gene copy number.
7. Sensitivity Analyses
Overall, univariate sensitivity analyses showed
assumptions on survival time, and PFS had a
major impact on the outcomes.[9-11,13,15,17] How-
ever, none of the varied cost and effectiveness
drivers led to alternative conclusions (i.e. domi-
nated became dominant treatment), indicating
robust results.
Carlson et al.[10] assumed equal survival and
PFS of docetaxel, pemetrexed and erlotinib. The
sensitivity analyses in the study by Carlson et al.[10]
showed that length of time in the progressive-
disease state has a huge influence on total costs,
as well as QALYs. As such, different assumptions
for PFS difference between the treatment arms
will influence the ICER. The sensitivity analyses
by Lewis et al.[16] assessed alternative scenarios,
such as equivalent overall survival and PFS,
equivalent treatment duration, equivalent utility
scores for PFS and the omission of adverse events
utilities, instead of the trial-based outcomes. Er-
lotinib remained the dominant treatment. Addition-
ally, cost and effectiveness drivers were varied
across ‘plausible ranges’ of-20% and+20%or-50%
and +50%, but no rationale behind the selection of
drivers, nor behind the 20% or 50% ranges, was
given.
8. Discussion
The available literature comparing the che-
motherapeutic drugs docetaxel, gemcitabine,
paclitaxel, pemetrexed, vinorelbine and erlotinib
with respect to health effect, costs and cost ef-
fectiveness was presented and discussed.
In our systematic review, we summarized the
findings of six reviews[19-24] that were published
between 2001 and 2010, and critically appraised
11 CEAs and CUAs published in that same
period.[9-18,25] The reviews provided little evi-
dence on our central research question, which
concerned the comparison of third-generation
drugs with one another. In two reviews,[10,16]
however, erlotinib was compared with docetaxel
and/or pemetrexed. The included evidence sug-
gested that erlotinib is cost saving compared with
the two alternative treatments, due to equal or
better survival, its oral administration and its fa-
vourable toxicity profile. None of the six reviews
that we included were conducted according to the
guidelines for systematic reviews.[7,36] Of six re-
views, three did not report a search strategy nor
any inclusion criteria,[18,22,23] and only one review
assessed the quality of the identified studies.[23] In
addition, all reviews included abstracts, which
made the obtained information less transparent.
The evidence generated by the 11 fully pub-
lished CEAs and CUAs can be summarized as
follows. In two studies on first-line treatment,[14,18]
gemcitabine+cisplatin was cost effective compared
with paclitaxel+cisplatin. In addition, gemcitab-
ine+cisplatin was cost effective compared with
paclitaxel+carboplatin, docetaxel+cisplatin and
vinorelbine+cisplatin.[14] However, pemetrexed+
cisplatin was more cost effective than gemcitabine+
cisplatin in the subgroup of patients with non-
squamous-cell carcinoma.[12] In second-line treat-
ment, docetaxel was cost effective compared with
BSC in two studies.[11,15] The evidence on peme-
trexed was contradictory: it was a cost-effective
option compared with docetaxel in one study[17]
but not in another.[10] Erlotinib was cost effective
compared with placebo,[9] docetaxel[10,16] and
pemetrexed.[10]
Although there were no CEAs on gefitinib com-
pared with another new agent or BSC, the IPASS
trial (Iressa Pan-Asia Study) showed a better
response rate and PFS in patients with a EGFR
gene mutation in the first-line setting.[37] More-
over, Chouaid et al.[38] evaluated the economic
impact of gefitinib in a third-line treatment set-
ting in a model-based study, and found the costs to
be acceptable from a healthcare payer perspective.
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As this study was a costing study, it was not in-
cluded in our review.
A combination therapy of a third-generation
agent and a platinum agent is recommended
as first-line treatment in patients with stage IV
NSCLC in US, UK and Dutch guidelines.[2,3,39]
These recommendations are based on clinical ef-
fectiveness rather than cost effectiveness. In terms
of clinical effectiveness, no preference for any
particular agent is indicated in these guidelines.
The current review provides the opportunity to
include cost-effectiveness arguments in decision
making concerning optimal chemotherapeutic
treatment in advanced NSCLC. Unfortunately,
we found no single third-generation drug to un-
equivocally dominate other agents, and the num-
ber of studies available to adequately compare
the agents with one another was low. Individual
CEAs may have influenced local treatment up-
take of particular agents, but this is difficult to
establish because patient registries showing ac-
tual clinical use are lacking.
None of the included studies used a societal
perspective for their analyses, although this is
recommended in economic evaluations.[36] For
advanced NSCLC, however, the improvement
in disease-free survival can be expected to have
no effect on patient-related loss-of-productivity
costs. On the other hand, there may be loss-of-
productivity costs for family and caregivers, and
other direct costs, such as travel costs associated
with intravenous administration, which may also
be incurred by the patient and their family or
caregivers. In the US, it has been estimated that
death from lung cancer will account for 27% of
the total costs of productivity loss due to cancer
in the coming 10 years.[40]
In most of the CUAs included in this review,
QALYs were based on generic EQ-5D studies
and, in one CUA,[17] QALYs were based on the
standard gamble approach. Although the QALY –
a generic measure of health benefit – is recom-
mended by NICE, the NHS and other health
authorities, its use for certain medical conditions
is questionable. Three main limitations of using
QALYs in cancer were stressed in a review by
Garau et al.[41] First, concerning QALYs based
on the EQ-5D, lack of sensitivity has been found
in measuring changes in the health states of can-
cer patients. Second, the methodology for valu-
ing health states assumes that individuals are
willing to trade a constant proportion of their life
expectancy to obtain a proportional improve-
ment in health benefit, regardless of their life ex-
pectancy. It has been suggested that for cancer
patients – especially NSCLC patients, who have a
short life expectancy – this assumption (based on
a 10-year framework) may not reflect their trade-
off preferences. Third, a growing body of evi-
dence indicates that patients tend to value a given
health state more highly than non-patients. In
addition to these limitations, in a meta-analysis
of utility values for lung cancer, the identity of the
responder (patient vs non-patient) was found to
have a significant impact on the utility value.[42]
It is clear that the methods currently being used
to assess health benefit are far from perfect when
evaluating healthcare technologies for a terminal
stage of disease, such as advanced NSCLC. The
gained utilities as an outcome measure in the
CUAs included in the present review were based
on generic EQ-5D studies and, therefore, in view
of these methodological limitations, they should
be interpreted cautiously.
In general, comparing the results of CEAs is
difficult because of differences in country, per-
spective and year of publication.[36,43] There is a
wide range of factors that limit the generalizability
of results over time and between health systems
and healthcare settings, including the context-
dependency of resource use, different decision
contexts and budget constraints.[44] The CEAs
included in the present study differed, for example,
in study design (trial based vs model based), time
horizon, treatment dosage and infusion time.
Model-based studies were difficult to compare be-
cause of different assumptions regarding model
structure and different calculations of parameter
values. The studies by Carlson et al.[10] and Lewis
et al.[16] were both modelling studies based on the
same two trials. Carlson et al.[10] assumed PFS to
be equal in all treatment arms, whereas Lewis
et al.[16] used the trial data for PFS. The trial
data showed a longer PFS for erlotinib than for
docetaxel.[32,34] As such, the results in the study
by Carlson et al.[10] are probably biased against
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erlotinib. The studies by Leighl et al.[15] andHolmes
et al.[11] were also based on the same trial. Holmes
et al.[11] did not include costs of toxicity treat-
ment, while Leighl et al.[15] did. Although both
studies concluded that docetaxel was cost effec-
tive compared with BSC, the incremental costs
for docetaxel were higher in the study by Leighl
et al.[15] Similarly, the incremental survival for
docetaxel differed in the two studies due to dif-
ferent methods of calculating survival.
A related issue is that none of the included
studies defined BSC, suggesting potential varia-
tions between trials in the type of supportive care.
This lack of clarity has been discussed previous-
ly.[45] It complicates the interpretation of cost-
effectiveness results for new agents compared with
BSC within studies, and threatens the validity of
comparisons between studies with a BSC reference
arm.
8.1 Quality of the Evidence
The methodological quality assessment show-
ed that the quality of the studies was acceptable,
although a few items were consistently under-
reported. In addition, some shortcomings could
not be assessed with the checklist by Drummond
and Jefferson.[6] For example, there is no question
that addresses the inclusion of all relevant cost
items. We found that none of the studies clearly
described whether costs for palliative care or
terminal care were included. With respect to the
quality of the modelling studies, we found esti-
mates of the key parameters, model assumptions
or calculations to be poorly reported. Preferably,
economic evaluations would be more explanatory
in their intents and methods. More detailed and
transparent model descriptions would possibly
permit better comparisons between studies and,
as such, systematic reviews of economic evalua-
tions could generate stronger evidence for policy
makers.[44]
8.2 Strengths and Limitations
Although we searched three relevant data-
bases, we may have missed studies. We have tried
to minimize this risk by scanning the reference
lists of all included studies. Studies were limited
to those in the English or Dutch languages, which
may have precluded relevant studies published in
different languages. Additionally, publication bias
may have occurred, as industry-funded studies
with unfavourable findings may not have been
published.
For the purpose of this review, we specifically
restricted ourselves to economic evaluations con-
ducting CUAs and/or CEAs. Moreover, we re-
stricted our selection to studies that compared the
five third-generation drugs and the targeted
drugs erlotinib and gefitinib with one another or
BSC. This inclusion criterion greatly reduced the
number of initially selected studies. Although this
resulted in a relatively small number of included
studies, our strategy corresponds to our aim of
discovering whether any of the third-generation
agents is superior in terms of cost effectiveness.
Furthermore, it should be noted that the included
studies mainly concerned gemcitabine and doc-
etaxel. Other agents, such as vinorelbine and ge-
fitinib, were under-represented or absent in this
review. Only one study[14] included vinorelbine as
a comparator arm for gemcitabine.
9. Conclusions
Due to the lack of transparency concerning BSC,
the small number of studies included in this re-
view and the aforementioned heterogeneity be-
tween studies, strong conclusions cannot be drawn.
Nevertheless, there is reasonable consensus be-
tween the studies with respect to the direction of
differences in cost and health effects for a number
of drug comparisons. As such, we conclude that,
in first-line treatment, gemcitabine+cisplatin seems
a cost-effective treatment option, although peme-
trexed+cisplatin performs better in a non-squamous
population. In second-line treatment, docetaxel is a
cost-effective option compared with BSC. Erlotinib
may be a cost-effective alternative to docetaxel.
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